Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
50 WongE
COA / Lab results Evidence: Clinical trial Pros Triple GLP-1 / GIP / glucagon agonism in one peptide raises energy expenditure, not appetite alone Largest weight reduction reported for an incretin-class compound (~24% at 12 mg, 48-wk phase 2) Reductions in HbA1c, visceral fat and liver-fat content across trials Once-weekly subcutaneous dosing (albumin-bound half-life) Cons GI effects require gradual multi-week dose titration Newest of the GLP-1 class phase 3 (TRIUMPH) topline only
Researchers should calculate these relationships carefully before establishing their dosing protocol
In women, insulin resistance can lead to a condition called polycystic ovary syndrome (PCOS), which is characterized by high levels of androgens (male hormones) and irregular menstrual cycles
Int J Mol Med 2013
US$ 20.71
US$ 24.59
US$ 23.63
